As a Partner at ClearView, Chris has broad experience overseeing a range of engagements involving therapeutic area, disease and asset level growth strategy as well as strategic due diligence on in-licensing and M&A opportunities. He has worked across the pharmaceutical sector with emphasis in orphan diseases and transformational technologies.
Chris began his career at the National Institutes of Health where he served as an AAAS Science Policy Fellow within the National Institute of Diabetes, Digestive, and Kidney Diseases. While at the NIDDK, Chris helped set strategic direction for the Institute focusing on diabetes research and translational medicine.
Chris received his Ph.D. in pharmacology and molecular sciences as well as his Master of Public Health from Johns Hopkins University School of Medicine. Chris received his MBA from Northeastern University and he earned his B.S. in biochemistry and molecular biology from the Pennsylvania State University.